特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

滑膜肉腫:パイプライン分析

Synovial Sarcoma - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 321902
出版日 ページ情報 英文 359 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.84円で換算しております。
滑膜肉腫:パイプライン分析 Synovial Sarcoma - Pipeline Review, H1 2020
出版日: 2020年02月28日 ページ情報: 英文 359 Pages
概要

滑膜肉腫は、軟部組織に生じる腫瘍で、二相性または単相性で生じ、上皮細胞または紡錘細胞によって形成されています。

当レポートでは、滑膜肉腫に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などについて、体系的な情報を提供しています。

目次

イントロダクション

滑膜肉腫の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Adaptimmune Therapeutics Plc
  • Advenchen Laboratories, LLC
  • EpiZyme, Inc.
  • Immune Design Corp.
  • Karyopharm Therapeutics, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OncoTherapy Science, Inc.
  • タカラバイオ Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • AL-3818
  • 腫瘍学向け MAGE-A1/MAGE-A3/NY-ESO-1標的細胞免疫療法
  • CMB-305
  • エベロリムス
  • GSK-3377794
  • OTSA-101
  • ペンブロリズマブ
  • selinexor
  • SSTC-104
  • tazemetostat
  • TBI-1301

パイプライン製品の最新動向

開発が中止されたプロジェクト

製品開発のマイルストーン

  • 注目のニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Synovial Sarcoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Synovial Sarcoma - Pipeline by Accuronix Therapeutics Inc, H1 2020
  • Synovial Sarcoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2020
  • Synovial Sarcoma - Pipeline by Advenchen Laboratories LLC, H1 2020
  • Synovial Sarcoma - Pipeline by Apollomics Inc, H1 2020
  • Synovial Sarcoma - Pipeline by Biogenera SpA, H1 2020
  • Synovial Sarcoma - Dormant Projects, H1 2020
  • Synovial Sarcoma - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Synovial Sarcoma, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC12017IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Synovial Sarcoma - Pipeline Review, H1 2020, provides an overview of the Synovial Sarcoma (Oncology) pipeline landscape.

Synovial sarcoma is a soft tissue tumor occurring in the biphasic or monophasic type and consisting of epithelial and/or spindle cell components. Symptoms include swelling, mass that may or may not be accompanied by pain and limping or difficulty using legs, arms, hands or feet. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Synovial Sarcoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Synovial Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Synovial Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 11, 10, 8 and 1 respectively.

Synovial Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Synovial Sarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Synovial Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Synovial Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Synovial Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Synovial Sarcoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Synovial Sarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Synovial Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

TABLE OF CONTENTS

Introduction

  • Synovial Sarcoma - Overview
  • Synovial Sarcoma - Therapeutics Development
  • Synovial Sarcoma - Therapeutics Assessment
  • Synovial Sarcoma - Companies Involved in Therapeutics Development
  • Synovial Sarcoma - Drug Profiles
  • Synovial Sarcoma - Dormant Projects
  • Synovial Sarcoma - Discontinued Products
  • Synovial Sarcoma - Product Development Milestones
  • Appendix